Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
about
Highly efficient elimination of colorectal tumor-initiating cells by an EpCAM/CD3-bispecific antibody engaging human T cellsBispecific antibodies for cancer therapy: the light at the end of the tunnel?The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemiaPotential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemiaNovel immunotherapies in lymphoid malignanciesBlinatumomab: enlisting serial killer T-cells in the war against hematologic malignanciesNovel immunotherapies for hematologic malignanciesBispecific T-cell engagers for cancer immunotherapy.Are BiTEs the "missing link" in cancer therapy?Tumor regression in cancer patients by very low doses of a T cell-engaging antibodyThe CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope in the full-length but not a short splice variant of CEAClinical Pharmacology and Translational Aspects of Bispecific AntibodiesAn EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma.Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology "UniCAR".T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells.Antibody-based immunotherapy for malignant glioma.Bispecific antibodies engage T cells for antitumor immunotherapy.T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cellBispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab.Synthesis of bispecific antibodies using genetically encoded unnatural amino acids.Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapyRetargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Characterization of a novel single-chain bispecific antibody for retargeting of T cells to tumor cells via the TCR co-receptor CD8B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor ImmunityImpact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110Symmetry breaking: bispecific antibodies, the beginnings, and 50 years onRedirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomasBiodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor siteTargeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platformSystemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.Characterization of the first-in-class T-cell-engaging bispecific single-chain antibody for targeted immunotherapy of solid tumors expressing the oncofetal protein claudin 6Novel antibodies as anticancer agents.Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemiaBlinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.Human regulatory T cells kill tumor cells through granzyme-dependent cytotoxicity upon retargeting with a bispecific antibody.Self-assembled antibody multimers through peptide nucleic acid conjugation.
P2860
Q21136080-B17E44B0-F36C-4C9E-BFCC-9244C893C0AFQ24644083-DC2A0851-D076-420C-8581-0D8049C5FC50Q26744280-C9617AEC-87BD-4FC0-BA7C-3AF8EC8B6276Q26764903-918EDF52-E4DB-41DE-9A41-2F53E1AEEDD3Q26777394-9D5F2A6B-16DD-4947-A182-0074982634CFQ26865838-AB76F2BA-9DA8-42AD-8C72-15474D9710A7Q27004436-C386C062-B1A8-451D-A16D-BEB26E33948FQ27693313-59DA25F7-13D7-434A-8F57-60F138D7280AQ28083907-95E56C2F-ED73-4AE2-99FF-082015A280BFQ28290910-9DAC9E33-693D-4241-B041-15869FDD9845Q28730117-0105D13A-D1E8-4B2D-B59C-2632C7C578BBQ33648086-D9B3283B-4745-4910-B5A3-4B52AA1614A1Q33665884-8638307B-EC39-4677-9F08-3C72BD1D8C7BQ33761755-95202702-C251-484E-AF00-D48679C999ACQ34005156-57ADA3F0-792B-47EE-BEF4-D5F20D83ADD6Q34120472-3AD0438C-0D6D-40A6-A044-18B6F53C0A55Q34174334-2ABE6A95-D441-4F92-A760-23F86A2ACFD3Q34227769-FF6BEA08-7590-4DAC-8D44-99EF71D34869Q34517676-EB705709-EA9E-4CB7-81E1-5D79AABF6F48Q34548319-6D5B5267-64E8-46F4-B7B3-6DA1A9A0F34DQ34981971-3AEBFE53-7112-468E-AA8A-0C4433324E52Q34986422-1ECFBBF4-B5AE-42B6-AB7D-3E14986EF769Q35086515-90D7E8BC-FB88-4015-A6B7-974F16FBA8E2Q35152029-6EB2CE44-77C6-4B60-B8E3-453D329D067DQ35153908-53F72668-7283-4A10-8796-B3E431EF8C7DQ35613233-DE712A3A-3985-4668-BEA4-1630743C6612Q35824663-ECF74BB9-C2EC-4BD9-94EA-C5073BE2608CQ36050013-128AE7E3-14B6-4635-97B0-040BF3B128D5Q36131489-679DFF47-E0D0-4FCF-8A26-8919C85B57CCQ36211422-6047D6E4-981F-4A6D-8ABB-3C37B3B92109Q36411863-DB5B4D24-C1E2-4FD7-AF49-D0B32CEE7E7AQ36443107-CA907EB7-B99A-4484-9612-0325A79CFA9FQ36512160-0AD673BB-E520-4D63-AFCA-C9F5ADD6338FQ36711034-36736363-2150-43B6-A6B5-8665D637B618Q36821083-2C75AC03-34BE-4931-8AEB-7EFA2E2C15B0Q36832141-C3B86233-F575-472E-83B3-F4BCA039BBE5Q36834079-F9AC2B3F-043E-48E6-9D26-4119319DB5A5Q37378009-21AC4797-6FFB-4961-90FC-1D489DCE4C79Q37598166-F06B5CED-5FFB-4F71-9FCF-52D55109DE56Q37633102-438A7408-8908-49C2-8F1D-270BB2D8334F
P2860
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells.
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Induction of regular cytolytic ...... class I-negative tumor cells.
@ast
Induction of regular cytolytic ...... class I-negative tumor cells.
@en
type
label
Induction of regular cytolytic ...... class I-negative tumor cells.
@ast
Induction of regular cytolytic ...... class I-negative tumor cells.
@en
prefLabel
Induction of regular cytolytic ...... class I-negative tumor cells.
@ast
Induction of regular cytolytic ...... class I-negative tumor cells.
@en
P2093
P1433
P1476
Induction of regular cytolytic ...... class I-negative tumor cells.
@en
P2093
Andrea Romaniuk
Patrick A Baeuerle
Peter Kufer
Robert Hofmeister
Sonja Offner
P304
P356
10.1016/J.MOLIMM.2005.03.007
P577
2005-04-26T00:00:00Z